Paul Tudor Jones Xencor Inc Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Xencor Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 34,894 shares of XNCR stock, worth $594,593. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,894

Previous 30,774 13.39%

Holding current value

$594,593

Previous $582,000 20.45%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.7 - $21.65 $64,684 - $89,198	4,120 Added 13.39%	34,894 $701,000
Q2 2024 Aug 14, 2024	SELL	$18.21 - $24.5 $56,323 - $75,778	-3,093 Reduced 9.13%	30,774 $582,000
Q1 2024 May 15, 2024	BUY	$18.65 - $26.52 $96,849 - $137,718	5,193 Added 18.11%	33,867 $749,000
Q4 2023 Feb 14, 2024	BUY	$16.53 - $21.42 $473,981 - $614,197	28,674 New	28,674 $608,000
Q2 2023 Aug 14, 2023	BUY	$24.77 - $29.9 $21,871 - $26,401	883 Added 2.92%	31,102 $776,000
Q1 2023 May 15, 2023	BUY	$25.95 - $36.95 $8,070 - $11,491	311 Added 1.04%	30,219 $843,000
Q4 2022 Feb 14, 2023	BUY	$24.79 - $30.86 $741,419 - $922,960	29,908 New	29,908 $779,000
Q2 2022 Aug 15, 2022	SELL	$19.74 - $29.01 $418,270 - $614,692	-21,189 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$26.68 - $41.63 $565,322 - $882,098	21,189 New	21,189 $565,000
Q3 2021 Nov 15, 2021	SELL	$30.65 - $35.68 $783,168 - $911,695	-25,552 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$34.33 - $44.68 $877,200 - $1.14 Million	25,552 New	25,552 $881,000
Q2 2018 Aug 14, 2018	SELL	$28.41 - $42.41 $511,720 - $763,888	-18,012 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$21.18 - $33.78 $381,494 - $608,445	18,012 New	18,012 $540,000

Others Institutions Holding XNCR

# of Institutions

216

Shares Held

72M

Call Options Held

2.5K

Put Options Held

7.9K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.02B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account